Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting

Allergy, Asthma and Clinical Immunology

Volumn 9, Issue 1, 2013, Pages

  Braunstahl, Gert Jan ^a   Chlumský, Jan ^b   Peachey, Guy ^c   Chen, Chien Wei ^d  

^a SINT FRANCISCUS GASTHUIS   (Netherlands)

^b CHARLES UNIVERSITY   (Czech Republic)

^c Novartis Pharmaceutical UK Limited   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Anti immunoglobulin E; Omalizumab; Oral corticosteroid use; Registry; Uncontrolled persistent allergic asthma

Indexed keywords

CORTICOSTEROID; METHYLPREDNISOLONE; OMALIZUMAB; PREDNISOLONE; PREDNISONE;

ADULT; ALLERGIC ASTHMA; ARTICLE; ASTHMA; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; DRUG USE; DYSPNEA; FEMALE; GLOBAL EVALUATION OF TREATMENT EFFECTIVENESS; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OBSERVATIONAL STUDY; PNEUMONIA; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84891597546     PISSN: 17101484     EISSN: 17101492     Source Type: Journal    
DOI: 10.1186/1710-1492-9-47     Document Type: Article

References (25)

1. Hanania NA, Alpan O, Hamilos DL, Condemi JJ, Reyes-Rivera I, Zhu J, Rosen KE, Eisner MD, Wong DA, Busse W. Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. Ann Intern Med 2011, 154:573-582. 10.7326/0003-4819-154-9-201105030-00002, 21536936.
2. Humbert M, Beasley R, Ayres J, Slavin R, Hébert J, Bousquet J, Beeh KM, Ramos S, Canonica GW, Hedgecock S, Fox H, Blogg M, Surrey K. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005, 60:309-316. 10.1111/j.1398-9995.2004.00772.x, 15679715.
3. Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, Kovac SH, Spettell CM, Saag KG. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum 2006, 55:420-426. 10.1002/art.21984, 16739208.
4. Fardet L, Flahault A, Kettaneh A, Tiev KP, Généreau T, Tolédano C, Lebbé C, Cabane J. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. Br J Dermatol 2007, 157:142-148. 10.1111/j.1365-2133.2007.07950.x, 17501951.
5. Manson SC, Brown RE, Cerulli A, Vidaurre CF. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med 2009, 103:975-994. 10.1016/j.rmed.2009.01.003, 19372037.
6. Walsh LJ, Wong CA, Oborne J, Cooper S, Lewis SA, Pringle M, Hubbard R, Tattersfield AE. Adverse effects of oral corticosteroids in relation to dose in patients with lung disease. Thorax 2001, 56:279-284. 10.1136/thorax.56.4.279, 1746020, 11254818.
7. EMA Xolair SmPC http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/human/000606/WC500057298.pdf.
8. US Food and Drug Administration Omalizumab (Xolair®) prescribing information http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm126456.htm, US Food and Drug Administration.
9. Holgate ST, Chuchalin AG, Hebert J, Lötvall J, Persson GB, Chung KF, Bousquet J, Kerstjens HA, Fox H, Thirlwell J, Cioppa GD. Omalizumab 011 International Study Group: efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004, 34:632-638. 10.1111/j.1365-2222.2004.1916.x, 15080818.
10. Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P. Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma. Ann Allergy Asthma Immunol 2012, 109:59-64. 10.1016/j.anai.2012.04.015, 22727159.
11. Solèr M, Matz J, Townley R, Buhl R, OBrien J, Fox H, Thirlwell J, Gupta N, Della Cioppa G. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001, 18:254-261. 10.1183/09031936.01.00092101, 11529281.
12. Siergiejko Z, Świebocka E, Smith N, Peckitt C, Leo J, Peachey G, Maykut R. Oral corticosteroid sparing with omalizumab in severe allergic (IgE-mediated) asthma patients. Curr Med Res Opin 2011, 27:2223-2228. 10.1185/03007995.2011.620950, 21933100.
13. Brodlie M, McKean MC, Moss S, Spencer DA. The oral corticosteroid-sparing effect of omalizumab in children with severe asthma. Arch Dis Child 2012, 97:604-609. 10.1136/archdischild-2011-301570, 22685051.
14. Braunstahl G-J, Chen C-W, Maykut R, Georgiou P, Peachey G, Bruce J. The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma. Resp Med 2013, 107:1141-1151.
15. Braunstahl G-J, Leo J, Thirlwell J, Peachey G, Maykut R. Uncontrolled persistent allergic asthma in practice: eXpeRience registry baseline characteristics. Curr Med Res Opin 2011, 27:761-767. 10.1185/03007995.2011.557717, 21405947.
16. Molimard M, Buhl R, Niven R, Le Gros V, Thielen A, Thirlwell J, Maykut R, Peachey G. Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data. Respir Med 2010, 104:1381-1385. 10.1016/j.rmed.2010.06.001, 20599369.
17. Molimard M, de Blay F, Didier A, Le Gros V. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir Med 2008, 102:71-76. 10.1016/j.rmed.2007.08.006, 17920257.
18. Cazzola M, Camiciottoli G, Bonavia M, Gulotta C, Ravazzi A, Alessandrini A, Caiaffa MF, Berra A, Schino P, Di Napoli PL, Maselli R, Pelaia G, Bucchioni E, Paggiaro PL, Macchia L. Italian real-life experience of omalizumab. Respir Med 2010, 104:1410-1416. 10.1016/j.rmed.2010.04.013, 20483574.
19. Brusselle G, Michils A, Louis R, Dupont L, Van de Maele B, Delobbe A, Pilette C, Lee CS, Gurdain S, Vancayzeele S, Lecomte P, Hermans C, MacDonald K, Song M, Abraham I. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med 2009, 103:1633-1642. 10.1016/j.rmed.2009.06.014, 19619998.
20. Rottem M. Omalizumab reduces corticosteroid use in patients with severe allergic asthma: real-life experience in Israel. J Asthma 2012, 49:78-82. 10.3109/02770903.2011.637598, 22149205.
21. Niven R. A UK survey of oral corticosteroid use in patients treated with omalizumab [abstract]. Thorax 2007, 62(3):A98. P91.
22. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, van As A, Gupta N. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001, 108:184-190. 10.1067/mai.2001.117880, 11496232.
23. Bousquet J, Siergiejko Z, Świebocka E, Humbert M, Rabe KF, Smith N, Leo J, Peckitt C, Maykut R, Peachey G. Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. Allergy 2011, 66:671-678. 10.1111/j.1398-9995.2010.02522.x, 21255035.
24. Bousquet J, Rabe K, Humbert M, Chung KF, Berger W, Fox H, Ayre G, Chen H, Thomas K, Blogg M, Holgate S. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007, 101:1483-1492. 10.1016/j.rmed.2007.01.011, 17339107.
25. Wechsler ME, Wong DA, Miller MK, Lawrence-Miyasaki L. Churg-strauss syndrome in patients treated with omalizumab. Chest 2009, 136:507-518. 10.1378/chest.08-2990, 19411292.